Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TG01 |
| Trade Name | |
| Synonyms | TG-01|TG 01 |
| Drug Descriptions |
TG01 is a peptide-based cancer vaccine consisting of 7 RAS peptides specific to KRAS G12 and G13 mutations, which potentially induces RAS-specific antitumor immune response (PMID: 32063605). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C200465 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Balstilimab + QS21 + TG01 | Balstilimab QS21 TG01 | 0 | 1 |
| Daratumumab + Nivolumab + QS21 + TG01 | Daratumumab Nivolumab QS21 TG01 | 0 | 1 |
| Daratumumab + Nivolumab + TG01 | Daratumumab Nivolumab TG01 | 0 | 0 |
| Gemcitabine + Sargramostim + TG01 | Gemcitabine Sargramostim TG01 | 0 | 0 |
| QS21 + TG01 | QS21 TG01 | 0 | 2 |
| TG01 | TG01 | 0 | 0 |